Ira Klein, MD, Discusses Quality Measures in Oncology

About Us

Publications

AJMC TV

Events

Conferences

News

Authors

Essentials

Research

ACO Coalition

TEVR2012

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr. Klein says that measurement is a driver for value and healthcare in the future. Quality measures like QOPI and HEDIS allow oncologists to measure how they should be rewarded and recognized for making improvement.

This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.

More on AJMC.COM

Segment 11: A Responsibility to Very Carefully Use Tests

Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology and emphasizes the harm that can be done when tests are not used right.

Segment 10: Lack of Accountability

The healthcare system needs to create more accountability and a better education and measurement system in place to get people ordering tests more thoughtfully.

Segment 9: Who Should Order the Test?

Both Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, agree that the role of genetic counselors should be limited when order diagnostic tests in medical oncology.

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

Segment 6: Learning About CancerLinQ as It Rolls Out

Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.

Segment 5: Proper Use of Tests

Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.

Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market

Daniel F. Hayes, MD, discusses the FDA's announcement that it will begin to regulate laboratory-developed tests and his belief that it will not squash innovation in the field.